Economic impact of timely diagnosis and early referral in comprehensive cancer care in Mexico: the DERIVA strategy.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: suspected cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The estimated average savings amount to 4 106 834.94 ± 6 467 043.35 USD. [CONCLUSION] Early detection and treatment of certain types of cancer can lead to significant cost savings, contributing to the financial sustainability of the health system and to improved survival rates and quality of life for patients.
[OBJECTIVE] To estimate the savings of a strategy for early diagnosis and treatment of patients with suspected cancer.
APA
Arrieta Ó, Gómez-García AP, et al. (2026). Economic impact of timely diagnosis and early referral in comprehensive cancer care in Mexico: the DERIVA strategy.. Salud publica de Mexico, 68(1 (ene-feb)), 13-21. https://doi.org/10.21149/16606
MLA
Arrieta Ó, et al.. "Economic impact of timely diagnosis and early referral in comprehensive cancer care in Mexico: the DERIVA strategy.." Salud publica de Mexico, vol. 68, no. 1 (ene-feb), 2026, pp. 13-21.
PMID
41698265 ↗
DOI
10.21149/16606
Abstract 한글 요약
[OBJECTIVE] To estimate the savings of a strategy for early diagnosis and treatment of patients with suspected cancer.
[MATERIALS AND METHODS] A financial analysis of the savings was carried out using a timely diagnostic program DERIVA. Cancers with higher mortality in Mexico were evaluated under three scenarios of earlier stage diagnosis. Optimistic: stage III to II (8-40%) and IV to III (2.6-40%). Moderate: stage III to II (4-24%) and IV to III (1.3-24%). Conservative: stage III to II (1-7%) and IV to III (0.7-10%).
[RESULTS] Care in stage II is projected to increase by 13.85% for breast cancer and 5.13% for colorectal cancer, while stage III care for lung cancer is expected to rise by 14.1%. The estimated average savings amount to 4 106 834.94 ± 6 467 043.35 USD.
[CONCLUSION] Early detection and treatment of certain types of cancer can lead to significant cost savings, contributing to the financial sustainability of the health system and to improved survival rates and quality of life for patients.
[MATERIALS AND METHODS] A financial analysis of the savings was carried out using a timely diagnostic program DERIVA. Cancers with higher mortality in Mexico were evaluated under three scenarios of earlier stage diagnosis. Optimistic: stage III to II (8-40%) and IV to III (2.6-40%). Moderate: stage III to II (4-24%) and IV to III (1.3-24%). Conservative: stage III to II (1-7%) and IV to III (0.7-10%).
[RESULTS] Care in stage II is projected to increase by 13.85% for breast cancer and 5.13% for colorectal cancer, while stage III care for lung cancer is expected to rise by 14.1%. The estimated average savings amount to 4 106 834.94 ± 6 467 043.35 USD.
[CONCLUSION] Early detection and treatment of certain types of cancer can lead to significant cost savings, contributing to the financial sustainability of the health system and to improved survival rates and quality of life for patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
- Corrigendum to: "Narrowing the Gap: Understanding Lung Cancer Care Intervals and Their Barriers in Latin American Low and Middle-Income Countries" [Archives of Medical Research 56 (2025) 103202/Article Number ARCMED-D-24-00358].
- Correction: Perilesional edema diameter associated with brain metastases as a predictive factor of response to radiotherapy in non-small cell lung cancer.
- Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.